The global endometrial cancer diagnostics market size was valued at USD 21.4 billion in 2021 and is expected to reach USD 28.4 billion by 2028, at a CAGR of 5.4% during the forecast period 2022-2028. The uterus, often known as the womb, is a female organ found in the lower abdomen. It aids in the growth of the fetus till delivery. The abnormal development of cells in uterine tissues is referred to as uterine cancer. Endometrial carcinoma and uterine sarcoma are two forms of uterine cancer. Endometrial carcinoma originates in the uterus's lining, commonly known as the endometrium, however uterine sarcoma develops in the uterus's supporting network, which includes the bones, tissues, and muscles. Hyperplasia, which occurs primarily in women who have never had a kid, obesity, and an excessive intake of breast cancer treatment medications are all linked to the development of uterine cancer. Endometrial cancer is characterized by symptomatic behavior, with the most common symptoms being abnormal vaginal bleeding, pelvic discomfort, and sudden vaginal discharge. Uterine sarcoma, with exception of endometrial cancer, is asymptomatic and discovered at a later stage.

View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/endometrial-cancer-diagnostics-market/    

Due to rising prevalence of Endometrial Cancer and rising healthcare spending, the Endometrial Cancer Diagnostics Market is anticipated to expand at a substantial CAGR. Gynecologic Cancer Awareness Month takes place in September in the United States. Endometrial carcinoma is a commonly diagnosed cancer all over the world, according to the American Association for Cancer Research, so although uterine sarcoma is a rare form of cancer. Endometrial carcinomas account for approximately 68 percent of all uterine cancers, according to the CDC. Developing countries, such as India, also have a National Cancer Control Program, which was founded in 1975–76. This has helped to fund the creation of Regional Cancer Centers (RCCs), oncology wings in medical schools, and the acquisition of teletherapy machines. Cancer awareness campaigns are being held in this country, with the purpose of making women aware of the disorder.

The global endometrial cancer diagnostics market segmentation:

1) Type of Condition: Endometrioid Carcinoma, Serous Adenocarcinoma, Aden squamous Carcinoma, Carcinosarcoma.

2) Type of Test: Hysteroscopy, Endometrial Biopsy, Dilation and Curettage, Ultrasound, CT scan, MRI.

3) End-user: Diagnostic Centers, Hospitals, Ambulatory Surgical Centers.

Owing to the rising prevalence of Endometrial Cancer in North America, the United States is anticipated to be the leading market for Endometrial Cancer diagnostic. As per the National Institutes of Health, the United States has a high rate of Endometrial Cancer due to the increasing obesity population associated with poor lifestyles and an increase in the number of postmenopausal women.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=22224          

There are several industry players working in the endometrial cancer diagnostics market, which include Abbott Laboratories (U.S), Ariad Pharmaceuticals, Inc. (U.S), Merck & Co., Inc. (U.S), Becton, Dickinson & Co. (U.S), Siemens Healthcare Inc. (Germany), Hoffman-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc., etc. (UK)

About Precision Business Insights:

We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:

Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747